Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

RSS icon

Study published in The New England Journal of Medicine finds intra-arterial treatment for clot removal is more effective at treating stroke than standard medical care

Study results released today in The New England Journal of Medicine gave the world of stroke care more evidence that physicians are winning the battle against this debilitating disease, which affects as many as one in six people. 

Active trend analysis helps hospitals find & correct PCI device issues

Active and real-time is better, especially when assessing device safety in the general population. A Massachussetts-based hospital network analyzing the safety of PCI-related devices found that a real-time safety alert was able to change practices to improve patient safety and outcomes.

Thumbnail

LVAD replacement approach leads to better outcomes

Surgeons using a nonsternotomy approach to replace continuous flow left ventricular assist devices (LVADs) found patients had better survival, according to a study published online Dec. 10 in Annals of Thoracic Surgery.

Thumbnail

In 5-year analysis, PCI wins over CABG for cost but not outcomes

Some things don’t make decisions easier: PCI may be more cost-effective, but CABG has fewer long-term major adverse events, according to a study published in the Dec. 1 issue of Catheterization and Cardiovascular Interventions.

Hospital transfer times shape care for some STEMI patients

When every minute counts, delaying treatment can have enormous repercussions. An analysis of U.S. data finds that while door-to-balloon times have improved, many patients may still not receive care within the recommended 120 minutes, due in part to transfers to STEMI care centers.

Biodegradable DES passes in best-of-class analysis

A biodegradable drug-eluting stent (DES) proved to be noninferior to durable-polymer DES and both showed benefits over bare-metal stents (BMS) in the BASKET-PROVE II clinical trial. The results published online Nov. 19 in Circulation also raise questions about triggers for late complications.

Key antiplatelet presentation yields more questions than answers

Paul A. Gurbel, MD, director of the Sinai Center for Thrombosis Research in Baltimore, provides perspective on the Dual Antiplatelet Therapy study results presented at the American Heart Association conference in Chicago and future directions.  

New data from EVOLVE clinical program demonstrate synergy BioabsoRbable Polymer stent meets key performance endpoints

In the first successful U.S. pivotal trial of a bioabsorbable polymer stent, the Boston Scientific SYNERGY Everolimus-Eluting Bioabsorbable Polymer Platinum Chromium Coronary Stent System met its primary endpoint in this non-inferiority study, which evaluated the one-year rate of target lesion failure (TLF).

Displaying 1609 - 1616 of 2707

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.